Journal of Commercial Biotechnology welcomes new editorial advisory board members

By /

The Journal of Commercial Biotechnology is proud to announce the addition of two esteemed industry experts to its advisory board.

The new editorial board members are:

  • Ananda Mohan Chakrabarty, distinguished university professor at the University of Illinois at Chicago and noted for his genetically modified Pseudomonas bacteria that became the first genetically-engineered organism to gain a US patent as a result of the Supreme Court decision in Diamond vs. Chakrabarty. He is the co-founder of two companies, CDG Therapeutics Inc. in Chicago and Amrita Therapeutics in India.
  • Meir Perez Pugatch, Managing Director Pugatch Consilium; Chair, Division of Health Systems Administration, School of Public Health, University of Haifa, Israel

These esteemed individuals complement the existing editorial advisory board, which includes:

  • Mark Ahn, Principal, Pukana Partners, Ltd., USA, United States
  • John Avellanet, Cerulean Associates LLC, United States
  • Boris Bogdan, Partner, Avance, Basel GmbH, Switzerland
  • Arthur Boni, John R. Thorne Chair of Entrepreneurship; Associate Teaching Professor of Entrepreneurship; and Director, Donald H. Jones Center for Entrepreneurship, Tepper School of Business, Carnegie Mellon University, United States
  • Walter Bratic, Managing Director, Overmont Consulting LLC, United States
  • G. Steven Burrill, Chief Executive Officer, Burrill & Company, United States
  • Steven Casper, Henry E. Riggs Professor of Management, Keck Graduate Institute of Applied Life Sciences, United States
  • Vijay Chandra, Chairman & CEO, Strand Life Sciences Pvt Ltd, India and Consulting Professor, ISL/EE, Stanford University, United States
  • James Class, Director, Global Public Policy, Merck, United States
  • Jeremy Laurence Curnock Cook, Executive Chairman, Bioscience Managers Limited, United Kingdom
  • Iraj Daizadeh, Senior Manager, Amgen Inc, United States
  • Mitch DeKoven, Director – Reimbursement and Market Access, Health Economics & Outcomes Research, IMS Health, United States
  • Spencer G. Feldman, Shareholder, Greenberg Traurig, United States
  • Sharon Finch, Director, Medius Associates, United Kingdom
  • Hernan Garrido-Lecca, Chairman and CEO Bioinvest; Professor of Economics and Public Policy, Universidad de San Martín de Porres, Lima Peru and Former Minister of Health, Peru
  • Gerald S. Graham, Business and Management Consultant, Graham Consulting Group, United States
  • Dave Jensen, Managing Director, CareerTrax Inc., United States
  • Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development and Professor of Medicine, Tufts University School of Medicine, United States
  • John Khong, Owner, Niche Medical, J & M Technologies, Cell Sciences; Adjunct faculty, LKC Business School, Singapore management University, Singapore
  • Edward L. Korwek, Partner, Hogan Lovells, United States
  • Thomas J. Kowalski, Attorney at Law, Vedder Price P.C., United States
  • Leonard Lerer, Sudarskis & Partners, United Arab Emirates
  • Weijun Li, Senior Research Scientist, Global Biological Development, Bayer HealthCare Pharmaceuticals, United States
  • Bryan A. Liang, Professor of Anesthesiology & Director San Diego Center for Patient Safety, University of California San Diego School of Medicine; Professor of Law & Executive Director, Institute of Health Law Studies, California Western School of Law, United States
  • Kate Lynch, CEO, Generic Medicines Industry Association (GMiA), Australia
  • Barry Marenberg, Chief Intellectual Property Strategist, BJM BioPat Solutions, United States
  • Henry I. Miller, Senior Research Fellow of Scientific Philosophy & Public Policy, Hoover Institution, Stanford University, United States
  • Stefan Michael Miller, Associate, Dechert LLP, United States
  • Sudha Nair, Director, Global Business Development, Apotex Fermentation Inc., Canada
  • Robin Nott, Chair of the Laws Committee, Licensing Executives Society Britain and Ireland, United Kingdom
  • Meir Perez Pugatch, Chair Division of Health Systems Administration, School of Public Health, University of Haifa; Managing Director Pugatch Consilium, Israel
  • Rebecca Robins, Director, Europe, Business Development, Interbrand Wood Healthcare, United Kingdom
  • Anthony J Russo, Chairman and CEO, Russo Partners, United States
  • Stephen M. Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurial Programs and Venture Partner, Burrill & Company, United States
  • Simon Shohet, Practice Director, Pope Woodhead & Associates Ltd, United Kingdom
  • Grant Skrepenk, Assistant Professor, The University of Arizona College of Pharmacy and Investigator, Center for Health Outcomes and PharmacoEconomic Research, United States
  • Anthony Stevens, Director, Medical Options, United Kingdom
  • Philip Neal Sussman, Managing Partner, The Channel Group LLC, United States
  • Michael Vitale, Director of Commercialisation, Monash Asia-Pacific Centre for Science and Wealth Creation, Monash University, Australia
  • Stan Yakatan, Chairman, Katan Associates, United States

For more information, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com

Biotechblog
Scroll to Top